MedPath

Special Drug Use-results Survey for long-term use of Doxil injection 20mg (ovarian cancer aggravated after chemotherapy)

Not Applicable
Conditions
ovarian cancer aggravated after chemotherapy
Registration Number
JPRN-UMIN000015902
Lead Sponsor
Janssen Pharmaceutical K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
500
Inclusion Criteria

Not provided

Exclusion Criteria

NA

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety(Adverse Drug Reaction) Effectiveness(Antitumor efficacy)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath